METHODS FOR TREATING VIRAL INFECTIONS, ORGAN INJURY, AND RELATED CONDITIONS
Disclosed herein are new therapeutic methods comprising administering compounds that can stabilize HIF and inhibit HIF prolyl hydroxylase (HIF-PH). In particular, methods described herein can be useful for treating/preventing a disease or condition in patients in need thereof, such as a patient having a viral infection such as a respiratory and/or pulmonary viral infection (e.g., an infection such as COVID-19 or a coronavirus infection). Methods described herein can also be useful for treating/preventing organ injury (e.g. organ injury that occurs concurrently or as a result of an infection). For example, methods described herein can be useful for treating or preventing acute lung injury, acute respiratory distress syndrome (ARDS), cardiovascular injury, injury to the liver, kidney diseases, and/or multi-organ failure.
1 . A method of treating a respiratory viral infection, comprising administering to a patient in need thereof an oral, once daily dose of vadadustat, or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the respiratory viral infection is induced by or associated with a virus that could lead to viral pneumonia.
3 . The method of claim 1 , wherein the respiratory viral infection is induced by or associated with a coronavirus, an influenza A, an influenza B, a Rhinovirus, a respiratory syncytial virus (RSV), an adenovirus, a human parainfluenza virus (HPIV) or an enterovirus.
4 . The method of claim 1 , wherein the respiratory viral infection is induced by or associated with a coronavirus.
5 . The method of claim 4 , wherein the coronavirus is the SARS-CoV, MERS-CoV, or SARS-CoV-2.
6 - 8 . (canceled)
9 . The method of any claim 1 , wherein the respiratory viral infection is COVID-19.
10 . The method of claim 9 , wherein the respiratory viral infection induces a lung disease.
11 . The method of claim 10 , wherein the lung disease is selected from acute lung injury (ALI), bronchitis, pneumonia, pulmonary fibrosis, asthma, or acute respiratory distress syndrome (ARDS).
12 - 19 . (canceled)
20 . A method of treating or preventing a lung disease that is acute lung injury (ALI) in a patient having a respiratory viral infection, comprising administering to the patient an oral, once daily dose of vadadustat, or a pharmaceutically acceptable salt thereof.
21 . A method of treating or preventing a lung disease that is acute respiratory distress syndrome (ARDS) in a patient having a respiratory viral infection, comprising administering to the patient an oral, once daily dose of vadadustat, or a pharmaceutically acceptable salt thereof.
22 - 23 . (canceled)
24 . The method of claim 21 , wherein the respiratory viral infection is infection by a coronavirus.
25 . The method of claim 24 , wherein the coronavirus is the SARS-CoV, MERS-CoV, or SARS-CoV-2.
26 . The method of claim 20 , wherein the respiratory viral infection is COVID-19.
27 . The method of claim 20 , wherein the patient with acute lung injury develops acute respiratory distress syndrome (ARDS).
28 - 155 . (canceled)
156 . The method of claim 1 , wherein the patient has a positive diagnostic test for SARS-CoV-2.
157 - 158 . (canceled)
159 . The method of claim 1 , wherein vadadustat is administered at an initial dose of 900 mg per day.
160 . The method of claim 1 , wherein vadadustat is administered at a dose of 900 mg per day throughout the treatment period.
161 . The method of claim 1 , comprising administration of vadadustat a dose of 900-1800 mg per day.
162 - 164 . (canceled)
165 . The method of claim 1 , wherein vadadustat is administered in combination with another treatment.
166 - 167 . (canceled)
168 . The method of claim 1 , wherein the severity of disease is maintained or reduced following commencement of administering vadadustat to the patient.
169 . The method of claim 168 , wherein the severity of disease is assessed according to the following ordinal scale where increasing numbers denote increased severity:
Score
Descriptor
Patient State
0
No clinical or virological evidence of infection
Uninfected
Uninfected/ Ambulatory
1
Not hospitalized, no limitation of patient’s activities
Infected (Ambulatory)
2
Not hospitalized, limitation of patient’s activities and/or requiring home oxygen
3
Patient is hospitalized but does not receive oxygen therapy - no longer requires ongoing medical care
Infected -Hospitalized (Mild Disease)
Hospitalized but not intubated
4
Patient is hospitalized but does not require oxygen therapy -requiring ongoing care (COVID-19 related or otherwise)
5
Patient is hospitalized and requiring supplemental oxygen
Infected -Hospitalized (Severe Disease)
6
Patient is hospitalized and receives oxygen therapy that is non-invasive ventilation or high flow oxygen devices
Hospitalized and intubated
7
Patient is hospitalized and receives invasive mechanical ventilation and additional organ support such as pressors, renal replacement therapy (RRT), and/or extracorporeal membrane oxygenation (ECMO)
.
170 - 192 . (canceled)
193 . The method of claim 169 , wherein the patient has a heart injury and/or a lung injury.
194 - 198 . (canceled)